Hussein Yassine, MD, Keck School of Medicine at the University of Southern California, Los Angeles, CA, comments on the metabolism of omega-3 in the brain, which is altered in patients with Alzheimer’s disease (AD), particularly those who are APOE4 carriers. Dr Yassine highlights the potential of inhibiting the enzyme calcium-dependent phospholipase A2 (CplA2) to increase omega-3 levels and the development of a novel PET scan-based probe to image omega-3 brain uptake. This research aims to elucidate the pathways altering omega-3 metabolism in APOE4 carriers and to translate findings into clinical trials to prevent AD. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
